The Washington Post @washingtonpost
An experimental Alzheimer’s drug slowed cognitive and functional decline by 27 percent in a clinical trial, the sponsors of the medication said Tuesday, increasing the therapy’s chance for approval as soon as early next year. https://t.co/C9hW5tGe3z — PolitiTweet.org